XJPX
8095
Market cap118mUSD
Dec 05, Last price
456.00JPY
1D
-1.08%
1Q
-11.80%
Jan 2017
103.57%
Name
Astena Holdings Co Ltd
Chart & Performance
P/E
—
P/S
0.32
EPS
—
Div Yield, %
3.95%
Shrs. gr., 5y
4.15%
Rev. gr., 5y
-1.21%
Revenues
57.99b
+11.56%
Net income
-2.53b
L
CFO
4.85b
+194.92%
Dividend
Nov 27, 20259 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Astena Holdings Co., Ltd. manufactures and sells medicine-related products in Japan. The company's Fine Chemical division manufactures and sells active pharmaceutical ingredients and medical supplies for antipyretic, analgesic, anti-inflammatory, and vasoconstrictor areas. Its Medical division is involved in the biotechnology related business, such as the provision of drug development support services; and sale of medical equipment. The company's Health & Beauty Care, and Food division engages in the sale of over-the-counter drugs, food product materials, functional food product materials, and cosmetic ingredients; mail/Internet-ordered sales business; and OEM production of cosmetics. Its Industrial Chemicals division manufactures and sells surface finishing chemicals and other chemical products, such as products for PWBs, electronic devices, general platings, and semiconductors. The company was formerly known as Iwaki & Co., Ltd. and changed its name to Astena Holdings Co.,Ltd. in June 2021. Astena Holdings Co., Ltd. was founded in 1914 and is based in Chuo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑11 | 2023‑11 | 2022‑11 | 2021‑11 | 2020‑11 | 2019‑11 | 2018‑11 | 2017‑11 | 2016‑11 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||